Physician profile
Ravi Benjamin Berger
NPI 1659314250
$6,116.71
in general payments reported to CMS, 2019-2025
22 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $225 · 2021: $531 · 2022: $666 · 2023: $1,013 · 2024: $1,498 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,855.52 | 2020-2025 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Alcon Vision LLC | $1,085.91 | 2019-2025 | Rocklatan, Unity, Clareon |
| Sun Pharmaceutical Industries INC. | $692.13 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $323.40 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $305.69 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $278.46 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $275.60 | 2019-2023 | |
| Amgen INC. | $206.08 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $175.72 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $142.19 | 2019-2022 | |
| Allergan, INC. | $134.60 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $116.59 | 2022-2024 | Omidria |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.37 | 2019-2021 | |
| Abbvie INC. | $80.45 | 2022-2025 | Lumigan, Alphagan P |
| Shire North American Group INC | $63.07 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $53.53 | 2019 | |
| Thea Pharma INC. | $49.64 | 2025 | Iyuzeh |
| New World Medical,INC. | $43.94 | 2020-2023 | |
| Harrow Eye, LLC | $35.41 | 2025 | Vevye |
| Ocular Therapeutix, INC. | $35.36 | 2020-2021 | |
| Dompe US, INC. | $29.92 | 2024 | Oxervate |
| Merz Pharmaceuticals, LLC | $20.13 | 2023 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.